Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Imcheck Therapeutics S.A.S.
Headquarters: Marseille, France
Website: http://www.imchecktherapeut...
Year Founded: 2015
Status: Private
BioCentury | Oct 16, 2024
Discovery & Translation
Science Spotlight: Better genomic predictors for Black AML patients
BioCentury’s roundup of translational innovations also includes a method for continuous base edits, plus updates from Monte Rosa and ImCheck
BioCentury | Jul 10, 2024
Management Tracks
Promotions for Flagship’s Afzelius, Biondi come amid $3.6B raise
Plus: EveryONE names CEO and chairman and updates from Lunit, Quell, ImCheck, Aktis, Immunic and Curve
BioCentury | Nov 2, 2023
Management Tracks
Sam Raha named COO at Myriad
Plus: Endeavor hires a new CMO, and updates from Jasper, Syantra, Ocuphire, Senisca and more
BioCentury | Mar 23, 2023
Management Tracks
Treco to succeed Bolte as CEO of Inozyme
Plus: Seagen’s Siegall to be CEO at Morphimmune and updates from Jasper, Vividion and more
BioCentury | Oct 10, 2022
Data Byte
Andera latest European VC to close largest-ever fund
BioDiscovery 6 to deploy €456 million for EU, U.S. therapeutics, medtech investments
BioCentury | Jun 14, 2022
Finance
ImCheck raises over $100M to progress gamma delta T cell mAb
Andera, Earlybird-led series C should reach Phase II data for ICT01, plus progress butyrophilin-targeted pipeline
BioCentury | Nov 16, 2021
Product Development
With trial starts and a takeout, γδ therapies start coming of age
Company data at SITC and ASH for antibodies and cell therapies directing γδ T cells to kill cancers
BioCentury | Oct 23, 2021
Discovery & Translation
ESGCT preclinical roundup; plus Generation, Pionyr and more
BioCentury’s roundup of translational news
BioCentury | Sep 17, 2021
Product Development
Sept. 17 ESMO Quick Takes: EQRx and CStone report more positive PD-1 data
Plus updates from TCR2, Daiichi, ImCheck and Coherus
BioCentury | Jul 16, 2021
Translation in Brief
Baker lab catches up to DeepMind; plus Casebia, 10X Genomics and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 31